secwatch.observer — SEC 8-K summary
======================================

Issuer:     PULSE BIOSCIENCES, INC. (PLSE)
CIK:        0001625101
Form:       8-K
Filed at:   2025-09-02T23:59:59+00:00
Accession:  0001437749-25-028093
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Pulse Biosciences enrolls first patients in PRECISE-BTN study for benign thyroid nodules
--------------------------------------------------------------------------------

- First successful procedures using nsPFA Percutaneous Electrode System for benign thyroid nodules (BTNs).
- Multicenter IRB-approved study will enroll up to 50 patients across four sites.
- Endpoints include safety, nodule volume reduction, symptom relief, quality of life, and cosmesis at 1, 3, 6, 12 months.
- CEO notes ongoing commercial launch pilot phase alongside clinical study progression.
- Principal investigator reports early positive results and organ-sparing potential.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1625101/000143774925028093/0001437749-25-028093-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1625101/000143774925028093/plse20250829_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-25-028093

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer